May 08, 2019
BerGenBio ASA: Results for the First Quarter 2019
Apr 23, 2019
BerGenBio to Present NSCLC and AML Clinical Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 2019
Apr 02, 2019
BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance
Apr 02, 2019
BerGenBio Extends Phase II Trial With Bemcentinib and KEYTRUDA® in NSCLC to Include Patients With Disease Progression on Immune Checkpoint Inhibitor Therapy
Apr 01, 2019
BerGenBio: Bemcentinib in Combination With low-dose Chemotherapy Achieves Efficacy Endpoint in AML Patients
Mar 21, 2019
Kanazawa University Research: Origin of Resistance to Lung-cancer Drug Discovered
Feb 27, 2019
Tolero Pharmaceuticals to Present New Data Evaluating Investigational Agents TP-0903 and TP-0184 at AACR Annual Meeting 2019
Jan 21, 2019
BerGenBio Announces Start of Phase I Trial Evaluating ADCT-601, a Novel Anti-AXL ADC, in Patients With Advanced Solid Tumours
Jan 09, 2019
BerGenBio Announces Start of Phase I Trial Evaluating First-in-Class Anti-AXL Antibody BGB149
Jan 04, 2019
BerGenBio Announces Start of Phase II Investigator Initiated Trial Evaluating Selective AXL Inhibitor Bemcentinib in High-risk MDS
Dec 12, 2018
BerGenBio Presents Key Results From PhII Programme With Selective AXL Inhibitor Bemcentinib at DNB's 9th Annual Nordic Healthcare Conference
Dec 02, 2018
BerGenBio Reports 43% Response Rate With Bemcentinib Monotherapy in AXL Positive R/R AML/MDS Patients at ASH
Nov 15, 2018
Tolero Pharmaceuticals Presents Clinical Data of AXL Kinase Inhibitor TP-0903 Showing its Ability to Enhance Host Immune Responses to Tumors
Nov 13, 2018
BerGenBio ASA: Results for the Third Quarter 2018
Nov 06, 2018
BerGenBio Reports ~80% Improvement in PFS of AXL-positive vs AXL-negative NSCLC Patients in Bemcentinib + KEYTRUDA PhII Combination Trial
Nov 02, 2018
BerGenBio to Present Late-breaking Abstract on Phase II Trial of Bemcentinib in Combination With KEYTRUDA® in Advanced NSCLC at SITC
Oct 05, 2018
BerGenBio Enters Second Stage of Phase II Trial With Selective AXL Inhibitor bemcentinib in Combination With KEYTRUDA® in Patients With Advanced NSCLC
Sep 25, 2018
BerGenBio: Updated PhII Clinical Data With Selective AXL Inhibitor Bemcentinib Strengthens its Potential to Improve NSCLC Patient Outcomes
Sep 05, 2018
BerGenBio to Present Interim Phase 2 Clinical Data With Selective AXL Inhibitor Bemcentinib in Non-small Cell Lung Cancer at WCLC
Aug 30, 2018
BerGenBio to Present at the 20th Annual Global Investment Conference in New York City September 4-6, 2018